obiavi.info

Tirzepatide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulin-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) double-receptor agonist administered once a week. Both GLP-1 and GIP belong to incretin, which is a polypeptide secreted by the gastrointestinal mucosa. The former can bind to the receptors on the islet cells and stimulate insulin secretion, thus producing hypoglycemic effect, delaying gastric emptying and suppressing appetite, thus controlling body weight. The latter has the functions of inhibiting gastric acid, gastric Chemicalbook protease secretion, stimulating insulin release, inhibiting gastric peristalsis and empty. it can supplement the effect of GLP-1 receptor agonist. tirzepatide combines the effects of two insulin-promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes. The molecule consists of a peptide skeleton of 39 amino acids and a side chain at Lys20. Of the 39 amino acids, 37 are naturally occurring (or coded) and two are non-naturally occurring, non-coding amino isobutyric acid residues at positions 2 and 13